Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1650
Leo L. 1, Surico D. 2, Deambrogio F. 2, Scatuzzi A. 3, Marzullo P. 2, Tinelli R. 4, Molinari C. 2, Surico N. 2
1 Struttura Complessa di Ginecologia e Ostetricia, AUSL della Valle d’Aosta, Aosta, Italia;
2 Clinica Ginecologica e Ostetrica, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara, Italia;
3 Ad Artem Pharma S.r.l., Torino, Italia;
4 Ospedale Civile “Perrino”, Brindisi, Italia
AIM: We conducted a pilot study to evaluate the effectiveness of resveratrol absorbed orally, conveyed through a new patented technology that increases the absorption through the oral mucosa in treatment of hot flushes (HF) during menopause.
METHODS: This is a randomized controlled double-blind study with crossover design. From October 2012 to July 2014 we considered the first 50 patients enrolled at the Center for Menopause Maggiore Hospital of Charity of Novara, with diagnosis of physiological or surgical menopause. Each woman received a diary in which she indicated the weekly number of HF and the perceived intensity, in a 0-10 Scale (Visual Analogue Scale, VAS).
RESULTS: Reduction of the monthly number of vasomotor episodes. Resveratrol 16/28 (57.1%); P2/22 placebo (9.1%) <0.001. The resveratrol group gets a positive result 6.28 times more compared to the placebo arm (95% CI: 1.61-24.49). Improvement of the intensity of symptoms and improving quality of life: resveratrol 22/28 (78.6%); placebo 4/22 P (18.2%) <0.001. Resveratrol group obtained a positive result 4:32 times more than the placebo arm (95% CI: 1.74-10.71).
CONCLUSION: Resveratrol is effective in reducing the number of episodes vasomotor and the intensity of HF, with the transition from moderate/severe to mild symptoms in 78.6% of patients. Resveratrol has the characteristics to be an alternative therapy in the treatment of HF in menopause.